These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25268372)

  • 1. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
    Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
    Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Schwab CL; English DP; Roque DM; Bellone S; Lopez S; Cocco E; Nicoletti R; Rutherford TJ; Schwartz PE; Santin AD
    Gynecol Oncol; 2014 Oct; 135(1):142-8. PubMed ID: 25124161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
    Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
    Black JD; Lopez S; Cocco E; Bellone S; Altwerger G; Schwab CL; English DP; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Br J Cancer; 2015 Sep; 113(7):1020-6. PubMed ID: 26325104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
    Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Yadav G; Roque DM; Bellone S; Manavella DD; Hartwich TMP; Zipponi M; Harold J; Tymon-Rosario J; Mutlu L; Altwerger G; Menderes G; Ratner E; Buza N; Hui P; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Aug; 166(2):351-357. PubMed ID: 35641325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
    Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
    Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
    Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
    Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
    [No Abstract]   [Full Text] [Related]  

  • 13. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
    Schwab CL; English DP; Black J; Bellone S; Lopez S; Cocco E; Bonazzoli E; Bussi B; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Santin AD
    Gynecol Oncol; 2015 Oct; 139(1):112-7. PubMed ID: 26260909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
    Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.